Armata Announces New Treatment Candidate for P. Aeruginosa Infections in CF Patients
Armata Pharmaceuticals is going to target multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients with its new enhanced bacteriophage candidate AP-PA02, the company announced. AP-PA02Â is being developed to replace…